Nyheter

An ETF that invest in Immunotherapy

Publicerad

8 år sedan

den

21 juli, 2016

Redaktionen

The Loncar Cancer Immunotherapy ETF, An ETF that invest in Immunotherapy, seeks to track the LCINDX index. It is made up of a basket of companies

Loncar Cancer Immunotherapy ETF (CNCR), An ETF that invest in Immunotherapy

ABOUT THE FUND

The Loncar Cancer Immunotherapy ETF, An ETF that invest in Immunotherapy, seeks to track the LCINDX index. It is made up of a basket of companies that develop therapies to treat cancer by harnessing the body’s own immune system. Immunotherapy is a transformational field within the biotechnology space that is expected to become the foundational treatment for cancer over the next ten years. A sector ETF focusing on a unique technology like cancer immunotherapy allows investors to focus on interest areas more precisely than broad indices. LCINDX is an equal-weighted index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in this approach.

Click to enlarge

INVESTMENT RATIONALE

Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system’s dynamic nature and the way it can more precisely be tailored to fight a patient’s disease. Some immunotherapies have exhibited uncommon results in clinical trials.

Today, many new classes of cancer immunotherapies are being developed. These include checkpoint inhibitors (which are already FDA approved for melanoma and lung cancer), cancer vaccines, bispecific antibodies, and chimeric antigen receptor (CAR-T) technologies. With this distinct sector focus, the fund aims to help investors capture a growth area of the biotechnology space. At the same time, it will support this method of treating cancer by providing capital to public companies that are leaders in the space.

Click to enlarge

* Fund holdings and allocations are subject to change at any time and should not be interpreted as an offer of these securites.

INDEX PROVIDER

Loncar Investments LLC was founded by noted independent biotech investor and analyst Brad Loncar. Mr. Loncar regularly provides his unique insight and analysis on this market segment to the investment community via a variety of publishing platforms. Through Loncar Investments LLC, Mr. Loncar incorporates his extensive research into biotech companies and technologies to develop indexes focused on precise investment opportunities.

Click to enlarge

Disclaimer

The Fund’s investment objectives, risks, charges and expenses must be considered carefully before investing. The summary and statutory prospectuses contain this and other important information about the investment company, and it may be obtained by calling 800-617-0004. Read it carefully before investing. Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. The Fund will invest in immunotherapy companies which are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The costs associated with developing new drugs can be significant, and the results are unpredictable. The process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals with be obtained and maintained.

Liknande ämnen:CNCR Immunotherapy

Nästa

Bank of England…waiting for stagflation

Missa inte

Natural gas rally over-done

Fortsätt läsa

Annons

Klicka för att kommentera

Nyheter

EUPC ETF investerar i amerikanska aktier med låg justerade prisdynamik

Publicerad

14 timmar sedan

den

24 december, 2024

Redaktionen

Ossiam Shiller Barclays CAPE® US Sector Value TR UCITS ETF 1C (USD) (EUPC ETF) med ISIN LU1079841513, försöker följa Shiller Barclays CAPE® US Sector Value-index. Shiller Barclays CAPE® US Sector Value Strategy väljer från S&P 500 de fem sektorer med lägst relativ CAPE (cykliskt justerad prisinkomst). Den relativa CAPE-koefficienten utvärderar en sektors relativa kostnadsprestanda baserat på dess nuvarande och långsiktiga historiska priser och avkastning. Sedan beräknar metoden sektorn med lägst prisdynamik över en period av 12 månader, dvs. e. den sektor som presterade sämst under rapportperioden. Var och en av de återstående fyra sektorerna får samma viktning (25 %) och komponenterna i investeringsuniversumet anpassas varje månad.

Den börshandlade fondens TER (total cost ratio) uppgår till 0,65 % p.a. Ossiam Shiller Barclays CAPE® US Sector Value TR UCITS ETF 1C (USD) är den billigaste och största ETF som följer Shiller Barclays CAPE® US Sector Value-index. ETFen replikerar resultatet för det underliggande indexet syntetiskt med en swap. Utdelningarna i ETFen ackumuleras och återinvesteras.

Ossiam Shiller Barclays CAPE® US Sector Value TR UCITS ETF 1C (USD) är en mycket stor ETF med tillgångar på 2 537 miljoner euro under förvaltning. Denna ETF lanserades den 22 juni 2015 och har sin hemvist i Luxemburg.

Handla EUPC ETF

Ossiam Shiller Barclays CAPE® US Sector Value TR UCITS ETF 1C (USD) (EUPC ETF) är en europeisk börshandlad fond. Denna fond handlas på flera olika börser, till exempel Deutsche Boerse Xetra och London Stock Exchange.

Det betyder att det går att handla andelar i denna ETF genom de flesta svenska banker och Internetmäklare, till exempel DEGIRO, Nordnet, Aktieinvest och Avanza.

Börsnoteringar

Börs	Valuta	Kortnamn
XETRA	EUR	EUPC
London Stock Exchange	GBX	CAPU
Bolsa Mexicana de Valores	USD	UCAPN
London Stock Exchange	USD	UCAP
SIX Swiss Exchange	USD	UCAP

Fortsätt läsa

Nyheter

Valour Kaspa SEK spårar priset på kryptovalutan KAS

Publicerad

15 timmar sedan

den

24 december, 2024

Redaktionen

Valour Kaspa (KAS) SEK (Valour Kaspa SEK) med ISIN CH1108679379, är en börshandlad produkt (ETP) som spårar KAS, den infödda symbolen för Kaspa blockchain. Genom att använda sitt GhostDAG-protokoll bearbetar Kaspa block parallellt, vilket möjliggör snabb transaktionsavslutning och hög skalbarhet. KAS-tokenen används för transaktionsavgifter och nätverkssäkerhet genom mining. Med sin effektiva och decentraliserade design stöder Kaspa skalbara blockkedjeapplikationer, vilket ger både utvecklare och användare kraft.

Beskrivning

Valour’s Certificate-produktlinje erbjuder börshandlade produkter som uppfyller kraven, var och en helt säkrad av sina respektive digitala tillgångar. För att säkerställa säker kylförvaring samarbetar Valour med nivå 1-licensierade förvaringsinstitut som Copper. Handlade på reglerade börser och MTFer ger dessa certifikat transparent prissättning och likviditet, vilket stärker investerarnas förtroende för säkra digitala tillgångsinvesteringar. Valours grundprospekt är godkända av Finansinspektionen och uppfyller EUs krav på fullständighet, tydlighet och konsekvens.

Produktinformation

Namn	Valour Kaspa SEK
Emittent	Valour Inc
Basvaluta	SEK
Föraltningskostnad	1,9%
ISIN	CH1108679379
Valoren	110867937
WKN	A4A55Z
Förfallodag	Open-ended

Handla Valour Kaspa

Valour Kaspa (KASPA) (Valour Kaspa SEK) är en europeisk börshandlad produkt som handlas på bland annat Spotlight Stock Market.

Det betyder att det går att handla andelar i denna ETP genom de flesta svenska banker och Internetmäklare, till exempel DEGIRO, Nordnet, Aktieinvest, Levler och Avanza.

Börsnoteringar

Börs	Valuta	Kortnamn
Spotlight Stock Market	SEK	VALOUR KASPA SEK

Fortsätt läsa

Nyheter

Crypto markets drop, Powell hints at fewer cuts, and Ethereum ETFs record inflows

Publicerad

1 dag sedan

den

23 december, 2024

Redaktionen

The third week of December was rough for crypto prices. The Nasdaq Crypto Index™ (NCI™) fell 9.7%, led by lackluster performance from Bitcoin (-3.2%) Ethereum (-2.3%) and Solana (-6.4%). This negative performance comes after weeks of strong price action in the crypto market, fueled by a series of positive developments. On Wednesday, the Fed lowered rates once again but Chair Powell suggested these cuts may slow.

Bitcoin ETFs experience strong selling spree after positive streak of days

US spot Bitcoin ETFs experienced a record $680 million in net outflows on Thursday, ending a 15-day streak of positive flows totaling $6.7 billion. This could indicate potential profit-taking by investors, given Bitcoin’s impressive 119% appreciation since the start of the year. If we are indeed at the beginning of a bull market, corrections during this cycle are expected to be nominally larger, as BTC, currently valued at around $100,000, has the potential for further appreciation throughout this cycle.

Ether ETFs record inflows in December

ETH ETFs attracted $1.66 billion in new investments this December, accounting for 74% of their $2.24 billion total inflows since inception and reflecting growing institutional interest beyond Bitcoin. The strong inflow-to-market cap ratio signals rising confidence in Ethereum, potentially paving the way for a broader range of regulated crypto products to gain prominence.

From Hashdex: With the year’s end approaching, we would like to invite our readers to explore our Outlook 2025, as it offers key insights to help investors confidently navigate the crypto market in this upcoming year.